ONMD:NASDAQOneMedNet Corp Analysis

OneMedNet (ONMD) is trading at $0.77, barely above its calculated support of $0.735 and well below its 20‑day SMA of $0.91, indicating limited upside in the near term. The 14‑day RSI of 38.9 and a bearish MACD histogram reinforce a short‑term momentum weakness. Volume has remained stable, but the 30‑day volatility exceeds 100%, reflecting a highly erratic price pattern. Fundamentally, the company reports a 30% revenue decline, negative gross margin of –50% and operating losses exceeding $9.9 M, leaving a negative book value per share. Cash on hand of $0.233 M is dwarfed by $0.837 M of debt, and free cash flow is deeply negative, underscoring severe liquidity pressure. No dividend is paid, and the price‑to‑book ratio of –10 further signals that the market price is not justified by underlying assets.
The only material catalyst is the recent integration of the iRWD platform with Palantir Foundry, which the company touts as a “transformative step” and could unlock new subscription revenue streams. However, the growth narrative is still speculative, as the firm has yet to demonstrate profitable scaling of this solution. With a beta of 1.49 and a sector classified under Health Information Services, regulatory and data‑privacy risks are elevated. Geographic exposure across the U.S., Europe and the Middle East adds moderate geopolitical risk but is largely USD‑denominated, keeping currency risk low. Given the confluence of weak technical signals, deteriorating fundamentals, and high volatility, the stock appears overvalued relative to its financial health. Investors should therefore approach ONMD with caution, limiting exposure to short‑term speculation while monitoring the execution of its data‑platform partnership for any sign of sustainable growth.